. 2017 Mar 3;102(5):1440–1446. doi: 10.1210/jc.2016-4048

Table 1.

Baseline Characteristics of Both Patients and Response to Treatment

	Reference Range	Case 1			Case 2
Sex, age		Male, 18 y			Female, 8 y
Weight		68.3 kg			22.5 kg
Presentation		Hematuria, nephrocalcinosis			Polyuria, nephrocalcinosis, hypercalcemia
Rifampin dose		600 mg daily			300 mg daily
		Baseline	1 mo	10 mo	Baseline	11 mo (on treatment)	13 mo (off treatment × 2 mo)
Albumin adjusted calcium, mg/dL	8.9–10.4	10.5	9.6	9.6	10.7	10	11.5
Phosphorus, mg/dL	2.5–4.5	3.6	3.1	4.1	4.2	3.6	4.5
Alkaline phosphatase, U/L	184–415 (Case 1)	82	114	84	242	467	345
Alkaline phosphatase, U/L	0.2–0.73 (Case 2)	82	114	84	242	467	345
Intact PTH, pg/mL	9–69	2	13	16	3	31	3
Creatinine, mg/dL	0.3–0.8 (Case 1)	1.4	1.2	1.1	0.59	0.54	0.65
Creatinine, mg/dL	0.2–0.73 (Case 2)	1.4	1.2	1.1	0.59	0.54	0.65
25(OH)D₃, ng/mL	28 ± 27	102	83	65	23	16	35
1,25-dihydroxyvitamin D₃, pg/mL	56 ± 27	99	53	59	55	58	76
24,25-dihydroxyvitamin D₃, ng/mL	1.6 ± 1	Undetectable^a	0.2	0.1	Undetectable	0.1	0.1
25-hydroxyvitamin D3/24,25-dihydroxyvitamin D₃, ng/ng	22 ± 13	N/A^b	415	650	N/A	160	350
4β,25-dihydroxyvitamin D₃, pg/mL^c	53 ± 34	275	594	528	N/A	82	56.7
4β,25-dihydroxyvitamin D₃/25-hydroxyvitamin D₃, (10⁻³)^c	2.1 ± 0·7	2.7	7.2	5.4	N/A	3.7	1.3

^{^a}

Test was performed, but the concentration was below the detectable limits of the assay.

^{^b}

Not tested.

^{^c}

4β,25-dihydroxyvitamin D₃ and the 4β,25-dihydroxyvitamin D3/25-hydroxyvitamin D₃ ratio are biomarkers of CYP3A4 induction.